This is significant given that blocking some LDL receptors such as lectin-like ox-LDL receptor 1 [(LOX-1) - the major receptor of ox-LDL] may be a potent therapeutic target for RA at both the local and systemic level which includes the cardiovascular response. The gene discussed is LDLR; the disease is rheumatoid arthritis.